Latest news with #VinicioVargas
Cision Canada
a day ago
- Business
- Cision Canada
Real-World Deployments Signal AI Healthcare Is Ready for Scale
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 30, 2025 /CNW/ -- The concept of AI in healthcare is no longer a novelty, experts are acknowledging AI algorithms, detection, and drug discovery are becoming indispensable tools. As medical errors continue to harm patients, healthcare experts are turning to AI to improve mistakes in medications, such as prescribing the wrong drug or wrong dose. As real-world deployment gains momentum, a number of tech and biotech firms are already translating AI healthcare innovation into clinical practice. Notable recent activity includes initiatives from Avant Technologies, Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Healwell AI Inc. (TSX: AIDX) (OTCPK: HWAIF), and WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF). Cathie Wood of Ark Invest recently highlighted new research from Mass General Brigham, where AI models were able to predict cancer survival outcomes based on facial images—an example she cited as evidence that healthcare could become AI's most transformative use case. Industry forecasts support that trajectory, with Statista estimating that the global AI healthcare market will grow from roughly $11 billion today to $188 billion by 2030, reflecting a compound annual growth rate of 37%. Avant Technologies, Inc. (OTCQB: AVAI), in collaboration with Ainnova Tech, is quietly building a foothold in the emerging field of predictive diagnostics. Its Vision AI platform is designed to identify disease markers at the earliest possible stage—sometimes before outward symptoms emerge—by leveraging artificial intelligence in combination with clinical data. In its latest move, Avant disclosed plans to integrate a patented technology that targets early-stage dementia detection, signaling an intentional broadening of its preventive care focus. The proposed tool uses proprietary algorithms alongside hardware and a five-minute blood test to flag dementia-associated risk factors well in advance of standard clinical methods. Avant is weighing both licensing and acquisition options for the technology, with global rights under consideration. Either route would strengthen the company's position in the neurodegenerative care space and complement its broader push into chronic illness screening. By expanding its platform's range without departing from its central thesis—early, accessible intervention— Avant is quietly aiming to reshape how and when critical conditions are first detected. "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years," said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC). "Adding the early detection of dementia that this patented technology presents us would go a long way to making us a leader in the industry of early disease detection." Vision AI is designed as a non-invasive platform that brings together retinal imaging, blood pressure readings, and routine lab data to generate personalized health assessments. Its core function is to estimate risk for common but often underdiagnosed chronic conditions—helping clinicians make earlier, more informed decisions with minimal burden on the patient. By analyzing just two retinal images and a short set of vital signs, the system runs four proprietary algorithms trained on more than 2.3 million clinical records. These algorithms evaluate indicators linked to cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. The technology's lightweight, modular design is intended to keep costs low while enabling use across a wide range of clinical settings—including those with limited access to specialist care. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." Alongside its dementia screening initiative, Avant is progressing toward a full acquisition of Ainnova Tech, its current development partner. The two firms are already operating under a shared entity— Ai-nova Acquisition Corp. (AAC) —and a completed merger would align leadership, simplify corporate structure, and create a more efficient framework for navigating regulatory milestones. A key FDA pre-submission meeting is scheduled for July, making the timing of this integration especially relevant. Internally, management views the consolidation as a strategic lever to accelerate U.S. market access while continuing to support ongoing deployments in international pilot programs. "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vargas. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product." While many AI-driven diagnostic platforms remain confined to controlled pilots or lab settings, Avant's Vision AI is already operating in live clinical environments across Latin America. Active deployments in Chile, Mexico, and Brazil are generating real-world data on safety, performance, and clinical usability—insights that are feeding directly into iterative improvements across the platform. Longer term, the company aims to unify a growing range of diagnostic tools under a single, streamlined system capable of delivering early-stage health insights from basic, non-invasive inputs. Backed by global platform rights through AAC, and supported by detection sensitivity levels reported above 90% in research cited by the NIH, Vision AI is quietly shaping into a scalable solution with potential utility across both developed and underserved healthcare systems. With dementia screening now entering the pipeline and additional modules under evaluation, Avant appears to be transitioning from early validation to broader execution—laying the groundwork for international expansion and a future U.S. launch. Tempus AI, Inc. (NASDAQ: TEM) has reached a major milestone, having supported close to 1,500 research projects since its founding in 2015. These efforts include around 1,000 biopharma partnerships and nearly 500 provider-led initiatives using Tempus' diagnostics, datasets, and modeling tools. The company's biological modeling lab alone has contributed to over 60 research projects focused on therapy selection and drug discovery. "From day one at Tempus, our mission has been to empower researchers with the data and insights they need to drive better outcomes," said Eric Lefkofsky, Founder and CEO of Tempus. "We have made significant progress toward that goal by delivering at a scale few others have achieved." With one of the largest libraries of multimodal data in healthcare, Tempus continues to scale its impact through AI-driven precision medicine. An independent safety board has endorsed the continuation of BioXcel Therapeutics, Inc.'s (NASDAQ: BTAI) pivotal Phase 3 SERENITY At-Home trial evaluating BXCL501 for agitation tied to bipolar disorders or schizophrenia. "We are pleased with the favorable DSMB meeting outcome and are excited about the upcoming data readout for our first at-home trial with BXCL501," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "Results are intended to help support a potential sNDA submission for label expansion of IGALMI® in the at-home setting — a sizeable unmet medical need given there are no FDA -approved therapies for bipolar or schizophrenia-related agitation in this environment." The fully enrolled trial involves over 200 patients who self-administer treatment during agitation episodes, with safety data tracked over 12 weeks. More than 150 participants have already received multiple doses. Topline results are slated for release in the third quarter of 2025 and may inform a future regulatory submission. Three subsidiaries under Healwell AI Inc. (TSX: AIDX) (OTCPK: HWAIF) and WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) have been selected as winners in Canada Health Infoway's 2025 Vendor Innovation Program, making up nearly half of the total awardees. The selected projects—Pentavere, Intrahealth, and OceanMD—are focused on real-world interoperability solutions that improve clinical workflows and enhance access to actionable patient data. "Intrahealth and Pentavere's recognition through the Vendor Innovation Program demonstrates the tremendous impact HEALWELL companies are having in the digital health landscape," said Dr. Alexander Dobranowski, CEO of HEALWELL. "Both companies are at the forefront of transforming healthcare delivery with innovative solutions that enhance data-driven care coordination, streamline workflows, and empower clinicians to deliver better patient outcomes." Each initiative will be deployed across multiple provinces and settings, including rural and Indigenous communities. "We are incredibly proud to see OceanMD, as part of WELLSTAR, recognized for its innovation in improving healthcare outcomes through digital technologies," said Amir Javidan, CEO of WELLSTAR — a subsidiary of WELL Health that focuses on digital health innovation and owns OceanMD, one of the three selected projects in the Vendor Innovation Program. "This recognition is a testament to the exceptional work our team is doing in transforming patient care, and we are excited to see the impact this will have in clinical settings across Canada." This recognition highlights both companies' leadership in advancing digital healthcare infrastructure in Canada. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
4 days ago
- Business
- Cision Canada
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders
VANCOUVER, BC, May 27, 2025 /CNW/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigham —where AI models identified cancer survival outcomes using facial photographs—as evidence that healthcare may become AI's " most profound application." As adoption moves from theory to practice, several tech and biotech players are already making real-world strides. Recent developments have come from Avant Technologies, Inc. (OTCQB: AVAI), Butterfly Network, Inc. (NYSE: BFLY), AptarGroup, Inc. (NYSE: ATR), AstraZeneca PLC (NASDAQ: AZN), and Relay Therapeutics, Inc. (NASDAQ: RLAY). According to Statista, the global economic impact of AI in healthcare stood at roughly $11 billion—but that figure is projected to reach $188 billion by 2030, representing a staggering 37% CAGR. Accenture forecasts an even greater long-term influence, estimating that AI could add $461 billion in value to the global healthcare sector by 2035. This surge in AI integration is unfolding within a system already projected to exceed $2.26 trillion—placing advanced diagnostics, early detection, and intelligent therapeutics at the heart of the next evolution in patient care. Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is working to position itself as a next-generation leader in predictive healthcare. Through its flagship platform, Vision AI, the company is developing a suite of AI-powered diagnostic tools aimed at detecting disease early—often before symptoms appear. Most recently, Avant announced it is exploring the integration of a patented technology designed for the early detection of dementia, marking a major expansion of its preventative screening capabilities. The proposed technology combines machine learning algorithms with hardware and a five-minute blood test to identify dementia-related risk factors well before traditional diagnoses. Avant is currently evaluating whether to acquire the intellectual property outright or license it globally. Either path would allow the company to add neurodegenerative screening to a platform already focused on chronic illness detection—expanding its clinical relevance while reinforcing its core strategy of early, accessible intervention. "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years," said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC). "Adding the early detection of dementia that this patented technology presents us would go a long way to making us a leader in the industry of early disease detection." For context, Vision AI is a non-invasive diagnostic platform that integrates retinal imaging, blood pressure, and basic lab data to assess an individual's risk for a range of chronic illnesses. Using just two retinal images and vital sign inputs, the system applies four proprietary algorithms—trained on more than 2.3 million clinical cases—to evaluate risk for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. The technology is designed to be fast, low-cost, and scalable, with a mission of enabling earlier and broader access to preventative care. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." In parallel to the dementia expansion, Avant is in advanced discussions to acquire Ainnova Tech outright. The two companies currently operate under the Ai-nova Acquisition Corp. (AAC) structure, and a completed merger would unify operations, reduce internal complexity, and streamline the path to regulatory approval. The timing is strategic, with a key FDA pre-submission meeting scheduled for July. Management believes that consolidation will strengthen Avant's U.S. market entry while continuing to support real-world deployments abroad. "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vargas. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product." While many early-stage AI healthcare platforms remain in pilot or prototype phases, Avant's Vision AI is already live in multiple clinical settings across Latin America. The platform is currently being used in Chile, Mexico, and Brazil, where it's generating safety, performance, and usability data from real-world patient populations. That clinical feedback is being used to refine the algorithms and prepare the system for broader adoption. The company's broader vision is to integrate a growing number of diagnostic tools into a single unified platform—one that can deliver actionable, early-stage health insights from simple inputs like imaging, vital signs, and blood biomarkers. With global rights to the Vision AI platform held through AAC, and detection sensitivity exceeding 90% according to research cited by the NIH, Avant believes it is well-positioned to offer scalable early detection solutions across multiple healthcare systems. With dementia screening now on the roadmap, and additional diagnostic modules under evaluation, Avant's trajectory appears to be accelerating—from early validation toward international scale, and ultimately toward U.S. market penetration. Butterfly Network, Inc. (NYSE: BFLY) delivered strong Q1 results with $21.2 million in revenue, up 20% from the prior year, while expanding its AI footprint in medical imaging. Its Butterfly Garden program added two new AI development partners, and one app—HeartFocus—earned FDA clearance for real-world cardiac assessment. "Our results highlight the strength of our opportunities in medical education and enterprise adoption, while marking continued progress across our strategic initiatives, Octiv™ and Butterfly HomeCare," said Joseph DeVivo, President, CEO and Chairman of Butterfly Network. "With multiple avenues for growth and a team built to execute, we're well-positioned to deliver on the guidance we committed, while continuing to advance innovation and uphold our technology leadership." These developments align with the company's broader strategy to combine semiconductor-based ultrasound with machine learning and clinical workflow software. AptarGroup, Inc. (NYSE: ATR), through its subsidiary Aptar Digital Health, and AstraZeneca PLC (NASDAQ: AZN) have entered a licensing agreement to develop AI-powered screening algorithms for chronic kidney disease (CKD), aiming to support early detection through routine eye exams. "With early detection and timely treatment, patients are likely to experience better health outcomes," said Romain Marmot, President of Aptar Digital Health. "This collaboration aims to enhance the overall quality of care for patients with CKD by providing an innovative and effective early detection tool." The algorithms—originally developed by AstraZeneca using thousands of biomarkers and clinical data points—will enable ophthalmologists to screen for CKD during retinal fundus imaging, similar to existing diabetic screening methods. "Chronic kidney disease remains one of the most significant global health challenges, with persistently low diagnosis rates," said Mina Makar, Senior Vice President, Cardiovascular, Renal and Metabolism, AstraZeneca. "This partnership with Aptar represents an exciting opportunity to drive innovation in chronic kidney disease management and our commitment to enhance diagnostics in novel ways. We are collaborating at scale to deliver sustainable solutions for millions of people living with chronic kidney disease worldwide." Relay Therapeutics, Inc. (NASDAQ: RLAY) is leveraging its AI-augmented Dynamo® platform to accelerate drug discovery in precision oncology and genetic diseases. In Q1 2025, the company reduced R&D spend and focused its pipeline to support key clinical milestones, including its ReDiscover-2 Phase 3 breast cancer trial and a new vascular malformations study. "2025 is a year of execution across a range of high value clinical programs," said Sanjiv Patel, M.D., President and CEO of Relay Therapeutics. "The ongoing changes to our cost base are designed to enable a full funding of key initiatives including generating topline data from the ReDiscover-2 trial and clinical proof-of-concept data in vascular malformations." With $710 million in cash and a runway projected through 2029, Relay is positioned to reach topline data readouts without additional financing. The company also completed a global out-license of RLY-4008, reinforcing its commitment to capital efficiency and focused innovation. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Miami Herald
4 days ago
- Business
- Miami Herald
Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform
LAS VEGAS, NEVADA / ACCESS Newswire / May 27, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are exploring options to integrate the early detection of dementia into Ainnova's proprietary, AI-powered platform technology, Vision AI. The addition would reinforce the Company's mission of expanding AI-powered early detection and preventative health solutions across the globe. Currently, the Company has identified a promising patented early disease detection technology specializing in the early detection of dementia and is exploring its options to either license the technology globally or potentially acquire the technology altogether. The patented technology combines AI algorithms and hardware based on a 5-minute blood test. Adding the early detection of dementia would expand the offerings in the Company's technology portfolio and enhance the broader vision of the partnership between Avant and Ainnova. The success of the Company's preventative screening platform involves the deployment of an automated, low-cost retinal imaging device integrated with the Vision AI platform to deliver comprehensive preventive risk screening. Presently, from just two retinal images, blood pressure and some lab test information, the Company's system uses 4 integrated algorithms to assess risks for: (i) cardiovascular disease (CVD), (ii) type 2 diabetes, (iii) liver fibrosis, and (iv) chronic kidney disease (CKD). Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the potential expansion of its technology portfolio, "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years. Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection." About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies Inc. Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact: Avant Technologies SOURCE: Avant Technologies Inc.
Associated Press
4 days ago
- Business
- Associated Press
Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform
LAS VEGAS, May 27, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ('Avant' or the 'Company'), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are exploring options to integrate the early detection of dementia into Ainnova's proprietary, AI-powered platform technology, Vision AI. The addition would reinforce the Company's mission of expanding AI-powered early detection and preventative health solutions across the globe. Currently, the Company has identified a promising patented early disease detection technology specializing in the early detection of dementia and is exploring its options to either license the technology globally or potentially acquire the technology altogether. The patented technology combines AI algorithms and hardware based on a 5-minute blood test. Adding the early detection of dementia would expand the offerings in the Company's technology portfolio and enhance the broader vision of the partnership between Avant and Ainnova. The success of the Company's preventative screening platform involves the deployment of an automated, low-cost retinal imaging device integrated with the Vision AI platform to deliver comprehensive preventive risk screening. Presently, from just two retinal images, blood pressure and some lab test information, the Company's system uses 4 integrated algorithms to assess risks for: (i) cardiovascular disease (CVD), (ii) type 2 diabetes, (iii) liver fibrosis, and (iv) chronic kidney disease (CKD). Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the potential expansion of its technology portfolio, 'This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years. Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection.' About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute 'forward-looking statements.' Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( ). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact: Avant Technologies, Inc. [email protected] Video - Logo - View original content to download multimedia: SOURCE Avant Technologies Inc.
Yahoo
4 days ago
- Business
- Yahoo
Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform
LAS VEGAS, May 27, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are exploring options to integrate the early detection of dementia into Ainnova's proprietary, AI-powered platform technology, Vision AI. The addition would reinforce the Company's mission of expanding AI-powered early detection and preventative health solutions across the globe. Currently, the Company has identified a promising patented early disease detection technology specializing in the early detection of dementia and is exploring its options to either license the technology globally or potentially acquire the technology altogether. The patented technology combines AI algorithms and hardware based on a 5-minute blood test. Adding the early detection of dementia would expand the offerings in the Company's technology portfolio and enhance the broader vision of the partnership between Avant and Ainnova. The success of the Company's preventative screening platform involves the deployment of an automated, low-cost retinal imaging device integrated with the Vision AI platform to deliver comprehensive preventive risk screening. Presently, from just two retinal images, blood pressure and some lab test information, the Company's system uses 4 integrated algorithms to assess risks for: (i) cardiovascular disease (CVD), (ii) type 2 diabetes, (iii) liver fibrosis, and (iv) chronic kidney disease (CKD). Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the potential expansion of its technology portfolio, "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years. Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection." About Ainnova Tech, is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact: Avant Technologies, Inc. info@ Video - - View original content to download multimedia: SOURCE Avant Technologies Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
